Entity

Time filter

Source Type

Nishi-Tokyo-shi, Japan

Patent
Nippon Chemiphar Co. | Date: 2013-01-10

The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R


Patent
Nippon Chemiphar Co. and Senju Pharmaceutical Co. | Date: 2014-06-27

Provision of an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, and a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like. A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.


Patent
Kyushu University and Nippon Chemiphar Co. | Date: 2015-07-24

A P2X wherein R


Patent
Nippon Chemiphar Co. and Kyushu University | Date: 2012-05-25

A P2X wherein R


Patent
Nippon Chemiphar Co. and Pharmacome LLC | Date: 2012-04-12

A modified G-protein-coupled receptor (GPCR), having modified ligand affinity is provided by binding a G-protein-coupled receptor to a polypeptide consisting of an amino acid sequence of SEQ ID NO: 1. Furthermore, agonists for or antagonists against the modified GPCR are screened using a transformant in which the modified GPCR has been expressed. This makes it possible to provide a technique for analyzing the function of many putative GPCRs whose entities have not been clarified.

Discover hidden collaborations